Overexpression of insulin like growth factor binding protein 5 reduces liver fibrosis in chronic cholangiopathy

Aleksandar Sokolović1, Paula S Montenegro-Miranda, Dirk Rudi de Waart

  • 1Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, University of Amsterdam, The Netherlands. a.sokolovic@amc.uva.nl

Insights

Insulin-like growth factor binding protein 5 (IGFBP5) overexpression in Abcb4(-/-) mice, a model for chronic cholangiopathy, reduced liver fibrosis. This protective effect was linked to decreased inflammation and oxidative stress, not altered bile composition.

Area of Science:

  • Hepatology
  • Molecular Biology
  • Biochemistry

Background:

  • The Abcb4(-/-) mouse model exhibits chronic cholangiopathy due to absent phospholipid secretion, leading to bile toxicity and liver pathology.
  • Insulin-like growth factor binding protein 5 (Igfbp5) expression increases in the livers of these mice, but its role in disease progression is unknown.

Purpose of the Study:

  • To investigate the effect of IGFBP5 induction on the progression of liver fibrosis in the Abcb4(-/-) mouse model of chronic cholangiopathy.

Main Methods:

  • Adeno-associated viral vectors (AAV) were used to overexpress IGFBP5 or green fluorescent protein (GFP) in hepatocytes of Abcb4(-/-) mice.
  • Liver fibrosis progression was assessed at 3, 6, and 12 weeks post-injection by analyzing serum parameters, collagen deposition, gene expression, inflammation, and oxidative stress.

Main Results:

  • Sustained hepatic expression of IGFBP5 and GFP was achieved via single AAV administration.
  • Compared to GFP controls, IGFBP5 overexpression significantly reduced liver weight, extracellular matrix deposition, and activated hepatic stellate cells up to 12 weeks post-treatment.
  • These protective effects were attributed to reduced inflammation, oxidative stress, and cell proliferation, independent of changes in bile composition.

Conclusions:

  • Overexpression of IGFBP5 demonstrates a protective effect against liver pathology in the Abcb4(-/-) mouse model of chronic cholangiopathy.
  • IGFBP5 ameliorates liver fibrosis by mitigating inflammation, oxidative stress, and cellular proliferation, suggesting therapeutic potential.

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...